Estimaciones de analistas de Wall Street para Inhibrx Biosciences Inc. (INBX): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-2.45 | ||
| 2026-08-13 | $-2.34 | $-2.28 | -2.6% |
| 2026-05-14 | $-2.15 | $-2.37 | +9.3% |
| 2026-03-19 | $-2.11 | $-2.08 | -1.4% |
| 2025-11-14 | $-2.28 | $-2.08 | -9.6% |
| 2025-08-13 | $-1.85 | $-2.92 | +36.6% |
| 2025-05-14 | $-2.80 | $-2.55 | -9.8% |
| 2025-03-17 | $-3.09 | $-2.88 | -7.3% |
Ratios de valoración
| Precio / Valor contable | -30.10 |
| EV / EBITDA | -12.68 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $6.7M | $8.4M | $8.6M | $9.1M | $12.8M | $7.1M | $2.2M | $1.8M | $200000 | $1.3M |
| Coste de Ventas | $17.0M | $25.5M | $33.5M | $47.9M | 0 | $2.7M | $110.2M | $1.2M | $2.3M | $2.5M |
| Beneficio Bruto | -$10.3M | -$17.1M | -$24.9M | -$38.8M | 0 | $4.4M | -$108.0M | $609000 | -$2.1M | -$1.2M |
| I+D | $17.0M | $25.5M | $33.5M | $47.9M | $73.5M | $71.4M | $110.2M | $190.6M | $203.7M | $113.0M |
| Generales y Administrativos | $1.6M | $2.6M | $4.7M | $9.0M | $6.8M | $9.7M | $21.1M | $29.4M | $127.9M | $23.3M |
| Gastos Operativos | $18.6M | $27.7M | $4.6M | $10.1M | $80.3M | $81.1M | $21.1M | $219.8M | $329.4M | $133.8M |
| Beneficio Operativo | -$12.1M | -$19.7M | -$29.5M | -$41.0M | -$67.4M | -$76.7M | -$129.1M | -$219.2M | -$331.4M | -$135.0M |
| EBITDA | -$11.9M | -$19.3M | -$28.8M | -$39.8M | -$66.4M | -$76.5M | -$125.8M | -$206.7M | $1.70B | -$125.4M |
| Gastos por Intereses | 0 | $2.1M | $1.5M | $5.7M | $10.8M | $5.2M | $16.1M | $31.8M | $13.5M | $12.2M |
| Beneficio Antes de Impuestos | -$12.9M | -$21.8M | -$30.9M | -$50.5M | -$75.6M | -$81.8M | -$145.2M | -$239.7M | $1.69B | -$140.1M |
| Impuestos | -$4.6M | $250000 | $96000 | $898000 | $3000 | $2000 | $3000 | $3000 | $2000 | $2000 |
| Beneficio Neto | -$8.3M | -$19.4M | -$31.2M | -$51.4M | -$76.1M | -$81.8M | -$145.2M | -$241.4M | $1.69B | -$140.1M |
| BPA | $-0.23 | $-0.68 | $-1.15 | $-1.41 | $0.00 | $-2.15 | $-3.62 | $-5.12 | $116.58 | $-9.04 |
| BPA Diluido | $-0.23 | $-0.68 | $-1.15 | $-1.41 | $0.00 | $-2.15 | $-3.62 | $-5.12 | $116.58 | $-9.04 |
| Acciones en Circulación (Diluidas) | $36.6M | $28.8M | $27.1M | $36.6M | $25.3M | $38.0M | $40.1M | $47.1M | $14.5M | $15.5M |
Precio
| Precio | $101.77 |
| Capitalización | $1.5B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: AMLX · ATAI · CVAC · ELVN · IMTX · NKTR · ORIC
Explorar sector: Healthcare · Biotechnology
Más secciones de INBX: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones